#China #Shanghai #Vaccine Development #Clover Biopharma #Nicholas Jackson

Clover Biopharmaceuticals Welcomes Nicholas Jackson, Ph.D.

In a noteworthy move within the biotech arena, Clover Biopharmaceuticals, Ltd. has appointed Nicholas Jackson, Ph.D., as the President of Global Research and Development (R&D) and Alliances. This strategic appointment aims to bolster the development of Clover's innovative vaccine candidates and expand its collaborative efforts on a global scale.

Dr. Jackson returns to Clover after a substantial career in vaccine and infectious disease research, spanning over 27 years. He is set to work closely with CEO Joshua Liang, focusing on advancing the company's combination vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus 3 (PIV3). This initiative comes on the heels of encouraging Phase I clinical trial results recently shared by Clover.

Joshua Liang expressed optimism, stating, "We are excited to welcome Nick back to Clover's leadership team. His extensive experience in leading global cross-border vaccine development and partnerships will be invaluable as we continue to advance our potential best-in-class and first-in-class RSV+hMPV±PIV3 combination vaccine candidates leveraging our validated Trimer-Tag platform."

Dr. Jackson's impressive credentials include leadership roles at renowned organizations such as GSK, Pfizer, and Sanofi, where he held the position of Head of Global Research for Sanofi Pasteur. His tenure includes extensive involvement in the vaccine research and early development activities on a global scale, which provides him with a unique perspective that will benefit Clover's strategic vision.

Regarding his return to Clover, Dr. Jackson noted, "I am honored to re-join Clover and look forward to helping advance and maximize global opportunities for Clover's RSV+hMPV±PIV3 combination vaccine candidates, which have recently announced positive Phase I clinical data in older adults." He continues to highlight the robust clinical safety database from Clover's Trimer-Tag platform technology, which boasts over 40,000 doses administered, enabling the transition to late-stage development and global opportunities.

Clover Biopharmaceuticals is committed to enhancing global public health through the development of innovative vaccines. The company aims to address the challenges posed by vaccine-preventable diseases with its diverse pipeline, integrating research, development, manufacturing, and commercial capabilities.

As Clover continues on its path to expanding its vaccine offerings, Dr. Jackson's leadership is expected to play a pivotal role in successfully navigating partnerships and advancing crucial projects. His deep expertise in vaccine research and development is aligned with Clover’s mission to play a crucial role in tackling infectious diseases and improving global public health outcomes.

In summary, with Nicholas Jackson, Ph.D., at the helm of Global R&D and Alliances, Clover Biopharmaceuticals is well-positioned to enhance its vaccine development initiatives. The cooperation and synergy among team members promise to drive forward the ambitious agenda aimed at defining a new era in vaccine innovation. This marks a significant chapter for Clover as it paves the way for future public health solutions through advanced vaccine technology, demonstrating their commitment to saving lives and enhancing health across the globe.

About Clover Biopharmaceuticals

Clover Biopharmaceuticals is a global, commercial-stage biotechnology enterprise dedicated to harnessing the power of innovative vaccines for the betterment of health worldwide. The company prides itself on its comprehensive approach and strong collaborations with various global organizations aimed at developing therapies that hold the promise of reducing the substantial burden of vaccine-preventable diseases.